CLOROX CO /DE/ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CLOROX CO /DE/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Jun 30, 2018 | $1.69B | Aug 14, 2018 |
| FY2018 | Mar 31, 2018 | $1.52B | Aug 14, 2018 |
| FY2018 | Dec 31, 2017 | $1.42B | Aug 14, 2018 |
| FY2018 | Sep 30, 2017 | $1.50B | Aug 14, 2018 |
| FY2018 | Jun 30, 2017 | $1.65B | Aug 14, 2018 |
| FY2018 | Mar 31, 2017 | $1.48B | Aug 14, 2018 |
| FY2018 | Dec 31, 2016 | $1.41B | Aug 14, 2018 |
| FY2018 | Sep 30, 2016 | $1.44B | Aug 14, 2018 |
| FY2018 | Jun 30, 2016 | $5.76B | Aug 14, 2018 |
| FY2018 | Jun 30, 2015 | $5.66B | Aug 14, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $7.10B | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | $7.09B | Aug 8, 2025 |
| FY2025 | Jun 30, 2023 | $7.39B | Aug 8, 2025 |
| FY2024 | Jun 30, 2022 | $7.11B | Aug 8, 2024 |
| FY2021 | Jun 30, 2021 | $1.80B | Aug 10, 2021 |
| FY2021 | Mar 31, 2021 | $1.78B | Aug 10, 2021 |
| FY2021 | Dec 31, 2020 | $1.84B | Aug 10, 2021 |
| FY2021 | Sep 30, 2020 | $1.92B | Aug 10, 2021 |
| FY2021 | Jun 30, 2020 | $1.98B | Aug 10, 2021 |
| FY2021 | Mar 31, 2020 | $1.78B | Aug 10, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Jun 30, 2017 | $1.65B | Aug 15, 2017 |
| FY2017 | Mar 31, 2017 | $1.48B | Aug 15, 2017 |
| FY2017 | Dec 31, 2016 | $1.41B | Aug 15, 2017 |
| FY2017 | Sep 30, 2016 | $1.44B | Aug 15, 2017 |
| FY2017 | Jun 30, 2016 | $1.60B | Aug 15, 2017 |
| FY2017 | Mar 31, 2016 | $1.43B | Aug 15, 2017 |
| FY2017 | Dec 31, 2015 | $1.35B | Aug 15, 2017 |
| FY2017 | Sep 30, 2015 | $1.39B | Aug 15, 2017 |
| FY2017 | Jun 30, 2015 | $5.66B | Aug 15, 2017 |
| FY2017 | Jun 30, 2014 | $5.51B | Aug 15, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $3.21B | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | $3.05B | Aug 8, 2025 |
| FY2025 | Jun 30, 2023 | $2.91B | Aug 8, 2025 |
| FY2024 | Jun 30, 2022 | $2.55B | Aug 8, 2024 |
| FY2023 | Jun 30, 2021 | $3.20B | Aug 10, 2023 |
| FY2022 | Jun 30, 2020 | $3.06B | Aug 10, 2022 |
| FY2021 | Jun 30, 2019 | $2.73B | Aug 10, 2021 |
| FY2021 | Jun 30, 2018 | $2.68B | Aug 10, 2021 |
| FY2021 | Jun 30, 2017 | $2.67B | Aug 10, 2021 |
| FY2020 | Jun 30, 2016 | $2.60B | Aug 13, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $810.00M | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | $280.00M | Aug 8, 2025 |
| FY2025 | Jun 30, 2023 | $149.00M | Aug 8, 2025 |
| FY2024 | Jun 30, 2022 | $462.00M | Aug 8, 2024 |
| FY2021 | Jun 30, 2021 | $97.00M | Aug 10, 2021 |
| FY2021 | Mar 31, 2021 | ($61.00M) | Aug 10, 2021 |
| FY2021 | Dec 31, 2020 | $259.00M | Aug 10, 2021 |
| FY2021 | Sep 30, 2020 | $415.00M | Aug 10, 2021 |
| FY2021 | Jun 30, 2020 | $310.00M | Aug 10, 2021 |
| FY2021 | Mar 31, 2020 | $241.00M | Aug 10, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $121.00M | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | $126.00M | Aug 8, 2025 |
| FY2025 | Jun 30, 2023 | $138.00M | Aug 8, 2025 |
| FY2024 | Jun 30, 2022 | $132.00M | Aug 8, 2024 |
| FY2023 | Jun 30, 2021 | $149.00M | Aug 10, 2023 |
| FY2022 | Jun 30, 2020 | $145.00M | Aug 10, 2022 |
| FY2021 | Jun 30, 2019 | $136.00M | Aug 10, 2021 |
| FY2020 | Jun 30, 2018 | $132.00M | Aug 13, 2020 |
| FY2019 | Jun 30, 2017 | $135.00M | Aug 14, 2019 |
| FY2018 | Jun 30, 2016 | $141.00M | Aug 14, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $1.12B | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | $1.17B | Aug 8, 2025 |
| FY2025 | Jun 30, 2023 | $1.18B | Aug 8, 2025 |
| FY2024 | Jun 30, 2022 | $954.00M | Aug 8, 2024 |
| FY2023 | Jun 30, 2021 | $1.00B | Aug 10, 2023 |
| FY2022 | Jun 30, 2020 | $969.00M | Aug 10, 2022 |
| FY2021 | Jun 30, 2019 | $856.00M | Aug 10, 2021 |
| FY2020 | Jun 30, 2018 | $837.00M | Aug 13, 2020 |
| FY2019 | Jun 30, 2017 | $810.00M | Aug 14, 2019 |
| FY2018 | Jun 30, 2016 | $806.00M | Aug 14, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $981.00M | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | $695.00M | Aug 8, 2025 |
| FY2025 | Jun 30, 2023 | $1.16B | Aug 8, 2025 |
| FY2024 | Jun 30, 2022 | $786.00M | Aug 8, 2024 |
| FY2023 | Jun 30, 2021 | $1.28B | Aug 10, 2023 |
| FY2022 | Jun 30, 2020 | $1.55B | Aug 10, 2022 |
| FY2021 | Jun 30, 2019 | $992.00M | Aug 10, 2021 |
| FY2020 | Jun 30, 2018 | $976.00M | Aug 13, 2020 |
| FY2019 | Jun 30, 2017 | $865.00M | Aug 14, 2019 |
| FY2018 | Jun 30, 2016 | $778.00M | Aug 14, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $220.00M | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | $212.00M | Aug 8, 2025 |
| FY2025 | Jun 30, 2023 | $228.00M | Aug 8, 2025 |
| FY2024 | Jun 30, 2022 | $251.00M | Aug 8, 2024 |
| FY2023 | Jun 30, 2021 | $331.00M | Aug 10, 2023 |
| FY2022 | Jun 30, 2020 | $254.00M | Aug 10, 2022 |
| FY2021 | Jun 30, 2019 | $206.00M | Aug 10, 2021 |
| FY2020 | Jun 30, 2018 | $194.00M | Aug 13, 2020 |
| FY2019 | Jun 30, 2017 | $231.00M | Aug 14, 2019 |
| FY2018 | Jun 30, 2016 | $172.00M | Aug 14, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $5.56B | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | $5.75B | Aug 8, 2025 |
| FY2024 | Jun 30, 2023 | $5.95B | Aug 8, 2024 |
| FY2023 | Jun 30, 2022 | $6.16B | Aug 10, 2023 |
| FY2022 | Jun 30, 2021 | $6.33B | Aug 10, 2022 |
| FY2021 | Jun 30, 2020 | $6.21B | Aug 10, 2021 |
| FY2021 | Jun 30, 2019 | $5.12B | Aug 10, 2021 |
| FY2021 | Jun 30, 2018 | $5.06B | Aug 10, 2021 |
| FY2021 | Jun 30, 2017 | $4.57B | Aug 10, 2021 |
| FY2020 | Jun 30, 2016 | $4.51B | Aug 13, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $5.08B | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | $5.26B | Aug 8, 2025 |
| FY2024 | Jun 30, 2023 | $5.56B | Aug 8, 2024 |
| FY2023 | Jun 30, 2022 | $5.43B | Aug 10, 2023 |
| FY2022 | Jun 30, 2021 | $5.74B | Aug 10, 2022 |
| FY2021 | Jun 30, 2020 | $5.31B | Aug 10, 2021 |
| FY2020 | Jun 30, 2019 | $4.56B | Aug 13, 2020 |
| FY2019 | Jun 30, 2018 | $4.33B | Aug 14, 2019 |
| FY2018 | Jun 30, 2017 | $4.03B | Aug 14, 2018 |
| FY2017 | Jun 30, 2016 | $4.21B | Aug 15, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $321.00M | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | $328.00M | Aug 8, 2025 |
| FY2024 | Jun 30, 2023 | $220.00M | Aug 8, 2024 |
| FY2023 | Jun 30, 2022 | $556.00M | Aug 10, 2023 |
| FY2022 | Jun 30, 2021 | $411.00M | Aug 10, 2022 |
| FY2021 | Jun 30, 2020 | $908.00M | Aug 10, 2021 |
| FY2020 | Jun 30, 2019 | $559.00M | Aug 13, 2020 |
| FY2020 | Jun 30, 2018 | $726.00M | Aug 13, 2020 |
| FY2020 | Jun 30, 2017 | $542.00M | Aug 13, 2020 |
| FY2019 | Jun 30, 2016 | $297.00M | Aug 14, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $1.23B | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | $1.23B | Aug 8, 2025 |
| FY2025 | Jun 30, 2023 | $1.25B | Aug 8, 2025 |
| FY2024 | Jun 30, 2022 | $1.56B | Aug 8, 2024 |
| FY2023 | Jun 30, 2021 | $1.58B | Aug 10, 2023 |
| FY2022 | Jun 30, 2020 | $1.58B | Aug 10, 2022 |
| FY2021 | Jun 30, 2019 | $1.59B | Aug 10, 2021 |
| FY2020 | Jun 30, 2018 | $1.60B | Aug 13, 2020 |
| FY2019 | Jun 30, 2017 | $1.20B | Aug 14, 2019 |
| FY2018 | Jun 30, 2016 | $1.20B | Aug 14, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $432.00M | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | $250.00M | Aug 8, 2025 |
| FY2024 | Jun 30, 2023 | $583.00M | Aug 8, 2024 |
| FY2023 | Jun 30, 2022 | $1.05B | Aug 10, 2023 |
| FY2022 | Jun 30, 2021 | $1.04B | Aug 10, 2022 |
| FY2021 | Jun 30, 2020 | $3.57B | Aug 10, 2021 |
| FY2020 | Jun 30, 2019 | $3.15B | Aug 13, 2020 |
| FY2019 | Jun 30, 2018 | $2.80B | Aug 14, 2019 |
| FY2018 | Jun 30, 2017 | $2.44B | Aug 14, 2018 |
| FY2017 | Jun 30, 2016 | $2.16B | Aug 15, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $167.00M | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | $202.00M | Aug 8, 2025 |
| FY2024 | Jun 30, 2023 | $367.00M | Aug 8, 2024 |
| FY2023 | Jun 30, 2022 | $183.00M | Aug 10, 2023 |
| FY2022 | Jun 30, 2021 | $319.00M | Aug 10, 2022 |
| FY2021 | Jun 30, 2020 | $871.00M | Aug 10, 2021 |
| FY2020 | Jun 30, 2019 | $111.00M | Aug 13, 2020 |
| FY2019 | Jun 30, 2018 | $131.00M | Aug 14, 2019 |
| FY2018 | Jun 30, 2017 | $418.00M | Aug 14, 2018 |
| FY2018 | Jun 30, 2016 | $401.00M | Aug 14, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $2.48B | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | $2.48B | Aug 8, 2025 |
| FY2024 | Jun 30, 2023 | $2.48B | Aug 8, 2024 |
| FY2023 | Jun 30, 2022 | $2.47B | Aug 10, 2023 |
| FY2022 | Jun 30, 2021 | $2.78B | Aug 10, 2022 |
| FY2021 | Jun 30, 2020 | $2.78B | Aug 10, 2021 |
| FY2020 | Jun 30, 2019 | $2.29B | Aug 13, 2020 |
| FY2019 | Jun 30, 2018 | $2.28B | Aug 14, 2019 |
| FY2018 | Jun 30, 2017 | $1.79B | Aug 14, 2018 |
| FY2017 | Jun 30, 2016 | $1.79B | Aug 15, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 6 | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | 2 | Aug 8, 2025 |
| FY2025 | Jun 30, 2023 | 1 | Aug 8, 2025 |
| FY2024 | Jun 30, 2022 | 3 | Aug 8, 2024 |
| FY2021 | Jun 30, 2021 | 0 | Aug 10, 2021 |
| FY2021 | Mar 31, 2021 | 0 | Aug 10, 2021 |
| FY2021 | Dec 31, 2020 | 2 | Aug 10, 2021 |
| FY2021 | Sep 30, 2020 | 3 | Aug 10, 2021 |
| FY2021 | Jun 30, 2020 | 2 | Aug 10, 2021 |
| FY2021 | Mar 31, 2020 | 1 | Aug 10, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 6 | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | 2 | Aug 8, 2025 |
| FY2025 | Jun 30, 2023 | 1 | Aug 8, 2025 |
| FY2024 | Jun 30, 2022 | 3 | Aug 8, 2024 |
| FY2021 | Jun 30, 2021 | 0 | Aug 10, 2021 |
| FY2021 | Mar 31, 2021 | 0 | Aug 10, 2021 |
| FY2021 | Dec 31, 2020 | 2 | Aug 10, 2021 |
| FY2021 | Sep 30, 2020 | 3 | Aug 10, 2021 |
| FY2021 | Jun 30, 2020 | 2 | Aug 10, 2021 |
| FY2021 | Mar 31, 2020 | 1 | Aug 10, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 122.69M | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | 124.20M | Aug 8, 2025 |
| FY2024 | Jun 30, 2023 | 123.82M | Aug 8, 2024 |
| FY2023 | Jun 30, 2022 | 123.15M | Aug 10, 2023 |
| FY2022 | Jun 30, 2021 | 122.78M | Aug 10, 2022 |
| FY2021 | Jun 30, 2020 | 126.20M | Aug 10, 2021 |
| FY2020 | Jun 30, 2019 | 125.69M | Aug 13, 2020 |
| FY2019 | Jun 30, 2018 | 127.98M | Aug 14, 2019 |
| FY2018 | Jun 30, 2017 | 129.01M | Aug 14, 2018 |
| FY2017 | Jun 30, 2016 | 129.36M | Aug 15, 2017 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $602.00M | Aug 8, 2025 |
| FY2025 | Jun 30, 2024 | $595.00M | Aug 8, 2025 |
| FY2025 | Jun 30, 2023 | $583.00M | Aug 8, 2025 |
| FY2024 | Jun 30, 2022 | $571.00M | Aug 8, 2024 |
| FY2023 | Jun 30, 2021 | $558.00M | Aug 10, 2023 |
| FY2022 | Jun 30, 2020 | $533.00M | Aug 10, 2022 |
| FY2021 | Jun 30, 2019 | $490.00M | Aug 10, 2021 |
| FY2020 | Jun 30, 2018 | $450.00M | Aug 13, 2020 |
| FY2019 | Jun 30, 2017 | $412.00M | Aug 14, 2019 |
| FY2018 | Jun 30, 2016 | $398.00M | Aug 14, 2018 |